U.K.-based CRO Chiltern has put itself up for sale as it continues the bullish M&A run for contract research groups that has seen a host of deals, JVs and mergers over the last 2 years.
This is according to Reuters, citing anonymous “people familiar with the matter,” who say that the company has hired investment bank Jefferies to orchestrate a sale in a deal that could value it at around $1.3 billion.
According to the newswire, “The sale process is in the early stages and will attract interest from private equity firms.” The company has not commented on the report.
Midsize CRO Chiltern has been beefing itself up over the years and back in 2015 bought up Theorem Clinical Research in a move to strengthen its global presence. This comes amid a boom in CRO and biopharma services deals over the past two years, with the biggest coming last October, when the world’s largest CRO and one of the biggest healthcare data and consulting firms combined to become one major $19 billion, 50,000-strong company, now known as QuintilesIMS.
And back in February of this year, acquisitive medical testing company LabCorp was also said to be prepared to spend $8 billion on one of the largest CROs in the world, PPD, hot on the heels of it buying up New Jersey-headquartered Covance in 2015 in a deal worth just over $6 billion. This rumor again came from Reuters.
And over the past 6 months, in an unprecedented move, Japanese pharma Takeda has forged a new joint venture with PRA Health to help run much of its R&D amid a major rejigging of its research ops.
By Ben Adams
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
